Current
6.9×
5-Year Average
5.2×
All-Time High
41.4×
All-Time Low
3.5×
P/B Ratio daily chart for Gilead Sciences (GILD)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
Historical P/B Ratio for Gilead Sciences (GILD) from 2001 to 2025
| 2025 | $152.44B | $22.62B | 6.7× | +0.8× | |
| 2024 | $115.28B | $19.33B | 6.0× | +1.5× | |
| 2023 | $101.10B | $22.83B | 4.4× | -0.6× | |
| 2022 | $107.48B | $21.24B | 5.1× | +0.7× | |
| 2021 | $91.20B | $21.07B | 4.3× | +0.3× | |
| 2020 | $73.12B | $18.20B | 4.0× | +0.4× | |
| 2019 | $82.26B | $22.52B | 3.7× | -0.1× | |
| 2018 | $80.69B | $21.39B | 3.8× | -0.8× | |
| 2017 | $93.63B | $20.44B | 4.6× | -0.4× | |
| 2016 | $94.24B | $18.89B | 5.0× | -2.9× | |
| 2015 | $145.31B | $18.53B | 7.8× | -1.4× | |
| 2014 | $141.96B | $15.43B | 9.2× | -0.9× | |
| 2013 | $115.19B | $11.37B | 10.1× | +4.1× | |
| 2012 | $55.73B | $9.30B | 6.0× | +1.5× | |
| 2011 | $30.19B | $6.74B | 4.5× | -0.5× | |
| 2010 | $29.30B | $5.86B | 5.0× | -1.1× | |
| 2009 | $38.94B | $6.37B | 6.1× | -4.8× | |
| 2008 | $46.59B | $4.27B | 10.9× | -1.4× | |
| 2007 | $42.64B | $3.46B | 12.3× | -4.0× | |
| 2006 | $29.70B | $1.82B | 16.4× | +8.4× | |
| 2005 | $23.97B | $3.03B | 7.9× | -0.2× | |
| 2004 | $15.09B | $1.87B | 8.1× | -3.7× | |
| 2003 | $11.76B | $1.00B | 11.7× | +0.1× | |
| 2002 | $6.67B | $571.34M | 11.7× | -2.2× | |
| 2001 | $6.27B | $452.44M | 13.9× | — |
- 20256.7×
- 20246.0×
- 20234.4×
- 20225.1×
- 20214.3×
- 20204.0×
- 20193.7×
- 20183.8×
- 20174.6×
- 20165.0×
- 20157.8×
- 20149.2×
- 201310.1×
- 20126.0×
- 20114.5×
- 20105.0×
- 20096.1×
- 200810.9×
- 200712.3×
- 200616.4×
- 20057.9×
- 20048.1×
- 200311.7×
- 200211.7×
- 200113.9×
About P/B Ratio at Gilead Sciences (GILD)
Gilead Sciences (GILD) P/B ratio is 6.9× as of June 5, 2026. The 5-year average is 5.2×. The sector median currently stands at 3.4×. The current ratio is at the 76th percentile of its own 10-year history.
Gilead Sciences (GILD) historical P/B ratio has ranged from a low of 3.5× (2022) to a high of 41.4× (2003) in the available daily series.
The price-to-book (P/B) ratio compares a company's market capitalisation to its book value of equity (total shareholders' equity) on the most recent quarterly balance sheet. It is calculated as market cap ÷ book value of equity (equivalent to share price ÷ book value per share). A P/B below 1× implies the market values the business below its accounting net worth; values well above 1× reflect intangible assets, brand value, or a high return on equity.
Gilead Sciences P/B Ratio by Year
Gilead Sciences P/B Ratio 2025: 6.7×
Gilead Sciences (GILD) P/B ratio in 2025 was 6.7×, expanded from 6.0× the prior year.
Gilead Sciences P/B Ratio 2024: 6.0×
Gilead Sciences (GILD) P/B ratio in 2024 was 6.0×, expanded from 4.4× the prior year.
Gilead Sciences P/B Ratio 2023: 4.4×
Gilead Sciences (GILD) P/B ratio in 2023 was 4.4×, contracted from 5.1× the prior year.
Gilead Sciences P/B Ratio 2022: 5.1×
Gilead Sciences (GILD) P/B ratio in 2022 was 5.1×, expanded from 4.3× the prior year.
Gilead Sciences P/B Ratio 2021: 4.3×
Gilead Sciences (GILD) P/B ratio in 2021 was 4.3×.
Sector peers by P/B Ratio — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by P/B Ratio — table
Healthcare peers of Gilead Sciences (GILD), ranked by P/B ratio.
| 2.9× | |
| 2.7× | |
| 2.6× | |
| 2.6× | |
| 2.5× | |
| 2.5× | |
| 2.4× | |
| 2.4× | |
| 2.3× | |
| 1.8× | |
| 1.8× | |
| 1.7× | |
| 1.7× | |
| 1.6× | |
| 1.5× | |
| 1.5× | |
| 1.5× | |
| 1.4× | |
| 1.4× | |
| 1.4× | |
| 1.2× | |
| 1.2× | |
| 1.1× | |
| 1.1× | |
| 0.8× |
- 2.7×
- 2.4×
- 2.3×
- 1.8×
- 1.7×
- 1.4×
- 1.4×
- 1.2×
- 1.1×
- 1.1×
- 0.8×
Frequently asked questions
Gilead Sciences (GILD) Key Financials
Charts, filings, and peer comparison for every metric